Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis
Public ClinicalTrials.gov record NCT01955733. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis: an Open-label Extension Trial
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective of this trial is to evaluate the long-term safety of BI 695500 in adult patients with moderately to severely active rheumatoid arthritis (RA) who have successfully completed treatment in Trial 1301.1.
Study identification
- NCT ID
- NCT01955733
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 91 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 82 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 31, 2013 (Actual)
- Primary completion
- Nov 18, 2015 (Actual)
- Completion
- Nov 7, 2016 (Actual)
- Last update posted
- Jan 18, 2018
2013 – 2016
United States locations
- U.S. sites
- 29
- U.S. states
- 17
- U.S. cities
- 29
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 1301.4.5585 Boehringer Ingelheim Investigational Site | Birmingham | Alabama | — | — |
| 1301.4.5727 Boehringer Ingelheim Investigational Site | Glendale | Arizona | — | — |
| 1301.4.5725 Boehringer Ingelheim Investigational Site | Phoenix | Arizona | — | — |
| 1301.4.5761 Boehringer Ingelheim Investigational Site | Little Rock | Arkansas | — | — |
| 1301.4.5765 Boehringer Ingelheim Investigational Site | El Cajon | California | — | — |
| 1301.4.5553 Boehringer Ingelheim Investigational Site | Lakewood | California | — | — |
| 1301.4.5527 Boehringer Ingelheim Investigational Site | Long Beach | California | — | — |
| 1301.4.5771 Boehringer Ingelheim Investigational Site | San Diego | California | — | — |
| 1301.4.5797 Boehringer Ingelheim Investigational Site | Santa Maria | California | — | — |
| 1301.4.5807 Boehringer Ingelheim Investigational Site | Upland | California | — | — |
| 1301.4.5809 Boehringer Ingelheim Investigational Site | Pembroke Pines | Florida | — | — |
| 1301.4.5567 Boehringer Ingelheim Investigational Site | Tampa | Florida | — | — |
| 1301.4.5561 Boehringer Ingelheim Investigational Site | Chicago | Illinois | — | — |
| 1301.4.5721 Boehringer Ingelheim Investigational Site | Columbia | Maryland | — | — |
| 1301.4.5811 Boehringer Ingelheim Investigational Site | Cumberland | Maryland | — | — |
| 1301.4.5507 Boehringer Ingelheim Investigational Site | Worcester | Massachusetts | — | — |
| 1301.4.5715 Boehringer Ingelheim Investigational Site | Grand Rapids | Michigan | — | — |
| 1301.4.5787 Boehringer Ingelheim Investigational Site | Omaha | Nebraska | — | — |
| 1301.4.5525 Boehringer Ingelheim Investigational Site | Toms River | New Jersey | — | — |
| 1301.4.5779 Boehringer Ingelheim Investigational Site | Brooklyn | New York | — | — |
| 1301.4.5717 Boehringer Ingelheim Investigational Site | Charlotte | North Carolina | — | — |
| 1301.4.5801 Boehringer Ingelheim Investigational Site | Dayton | Ohio | — | — |
| 1301.4.5549 Boehringer Ingelheim Investigational Site | Memphis | Tennessee | — | — |
| 1301.4.5729 Boehringer Ingelheim Investigational Site | Nashville | Tennessee | — | — |
| 1301.4.5757 Boehringer Ingelheim Investigational Site | Carrollton | Texas | — | — |
| 1301.4.5789 Boehringer Ingelheim Investigational Site | Corpus Christi | Texas | — | — |
| 1301.4.5705 Boehringer Ingelheim Investigational Site | Houston | Texas | — | — |
| 1301.4.5597 Boehringer Ingelheim Investigational Site | McKinney | Texas | — | — |
| 1301.4.5795 Boehringer Ingelheim Investigational Site | Beckley | West Virginia | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 14 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01955733, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 18, 2018 · Synced Sep 30, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01955733 live on ClinicalTrials.gov.